CPMG Inc’s Forte Biosciences FBRX Stock Holding History

CPMG Inc’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-92	Closed	-$377K	–	17
2019 Q1	$377K	Sell	92 -81	-47%	-$313K	0.05%	16
2018 Q4	$533K	Hold	173	–	–	0.05%	17
2018 Q3	$1.01M	Sell	173 -214	-55%	-$815K	0.07%	19
2018 Q2	$1.35M	Hold	387	–	–	0.13%	16
2018 Q1	$1.72M	Sell	387 -120	-24%	-$556K	0.19%	15
2017 Q4	$1.95M	Buy	+507	New	+$2.02M	0.2%	13

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

CPMG Inc's FBRX Position: Q2 2019 in Review

CPMG Inc sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 92 shares — an estimated $377K sold.

CPMG Inc first reported a position in FBRX in Q4 2017 and held it in 6 quarters. The position peaked at $1.95M in Q4 2017. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

CPMG Inc reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
CPMG Inc sold 92 Forte Biosciences shares in Q2 2019, an estimated $377K.
CPMG Inc first reported a position in Forte Biosciences in Q4 2017 and held it in 6 quarters.
CPMG Inc's Forte Biosciences position peaked at $1.95M in Q4 2017.
74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on CPMG Inc's 13F filing for Q2 2019, filed 14 Aug 2019.